Coherence principles in dose-finding studies
From MaRDI portal
(Redirected from Publication:3545408)
Recommendations
- Cumulative cohort design for dose-finding
- Design efficiency in dose finding studies
- Optimal designs for dose-finding studies
- Efficiency of bridging between related dose finding studies
- Performance Measures in Dose‐Finding Experiments
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- A Note on Multiple Testing Procedures in Dose Finding
Cited in
(25)- Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials
- Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
- Bayesian models and decision algorithms for complex early phase clinical trials
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- Adaptive prior variance calibration in the Bayesian continual reassessment method
- Incorporating individual and collective ethics into phase I cancer trial designs
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- scientific article; zbMATH DE number 4176221 (Why is no real title available?)
- Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
- Optimal designs for dose-escalation trials and individual allocations in cohorts
- Biometric practicesimple benchmark for complex dose finding studies
- Continual reassessment method for partial ordering
- Continual reassessment method with multiple toxicity constraints
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- Cumulative cohort design for dose-finding
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
- Posterior Predictive Design for Phase I Clinical Trials
- Adaptive clinical trial designs for phase I cancer studies
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
- Efficiency of bridging between related dose finding studies
- A product of independent beta probabilities dose escalation design for dual-agent phase I trials
- Continual reassessment and related dose-finding designs
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
This page was built for publication: Coherence principles in dose-finding studies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3545408)